Kornimate/medical-research-clean huggingface dataset:
rood's sensory motor training in sub-acute stroke

Conditions: Stroke

Summary: the aim of this randomized controlled trial is to determine the effects of rood's sensory motor training along with constraint induced movement therapy (cimt) in sub-acute stroke. two randomized groups of patients with stroke were treated with conservative physical therapy and the experimental group was given rood's smt and cimt in conjunction with conservative rehabilitation. both, male and female patients meeting the inclusion criteria were included. patients having other neurological disease, chronic disease, not compatible being participates in cimt or with any surgical intervention were excluded.

the study is aimed at determining the effects of rood's sensory motor training along with constraint induced movement therapy in sub-acute stroke and is being conducted in national institute of rehabilitation medicine islamabad and pakistan railway general hospital, rawalpindi (feb 2019-july 2019). sample size of the study is 36 patients, 36 were included in the study on the basis of inclusion criteria, 18 for each group. patients were allocated randomly and equally in each group. similar conservative rehabilitation protocol was designed for both control and experimental group except for experimental group had rood's sensory motor training and cimt training. patients were examined at 1st visit before administration of any treatment and at 6th week which was also the last one (after completing 6 weeks sessions at alternate days). baseline evaluation for demographics and assessment was taken. fugyl-meyer assessment scale(fma) and wolf motor function test(wmft) as measuring tools were used for first and 6th week assessment. 29 patients completed the study while 4 patient from control group and 3 patients from experiment group were lost to follow up and were considered drop outs.

Eligibility criteria:
inclusion criteria: * right \& left hemiplegia * ischemic \& hemorrhagic stroke * compatible with being participate in cimt i.e. 10ºwrist extension,10ºany two fingers extension,10ºthumb abduction * duration of stroke between 6 weeks to 6 months exclusion criteria: * not compatible with being participate in cimt * any other neurological disease e.g. parkinson's disease, brain tumors * chronic disease e.g. ischemic heart disease, tumors, diabetes mellitus * behaviors issues, not willing to participate * surgical intervention that hinders treatment and assessment * not well oriented to follow designed motor task

Keywords: stroke proprioceptive neuromuscular facility hemiplegia neurorehabilitation neural plasticity
neutrophil cd64 for early diagnosis of nosocomial infection in preterm newborns

Conditions: Nosocomial Infection

Summary: diagnosis of late-onset sepsis is difficult in the absence of specific clinical signs and biological markers in the infection initial phase .the aim of this study is to determine the performance of a new infection marker : neutrophil cd64 for early diagnosis in nosocomial infection (ni) in preterm newborns. methods : * monocentric prospective study including preterm newborn infants (\<37 weeks of gestationnal age ) with clinical suspicion of nosocomial infection in a neonatal intensice care unit (neonatal intensive care unit of montpellier, france). * patients will be enrolled in the study after informed consents. rapid and automated cd64 measurment will be realized during the conventional blood sample including c-reactive protein (crp), procalcitonin (pct) and blood culture. * broad-spectrum antibiotic therapy can be started on the advice of clinician and blinded the result of cd64. patients will be then classed in three groups using cdc criteria (center for disease control) : 1-no infection, 2-infection, 3-possible infection during the multidisciplinary staff. specificity, sensitivity, negative and positive value of cd64 will be calculated and the performances of crp, pct and cd64 will be compared. 153 patients are needed in the study enrolled during a period of 12 months. perspectives neutrophil cd64 monitoring might be help clinicians to manage nosocomial infections in neonates.cd64 allow to integrate in a decision algorithm with the determination of the best cut-off value to faster processing nosocomial infections and could help to reduce unnecessary antibioc therapy. a rapid technique for determination of cd64 should be readily available in our unit.


Eligibility criteria:
inclusion criteria: * preterm newborn (\<37 weeks of gestationnal age ) * undergoing symptoms of late-onset-sepsis * written informed consent obtained from the parents exclusion criteria: * patient undergoing antibiotic therapy * patient undergoing surgery in the last seven days, * patient with severe congenital malformation * necrotizing enterocolitis * parents unable to understand the purpose of the study * no affiliation to social security

Keywords: marker cd64 blood sample nosocomial infection preterm newborn
a clinical evaluation of two contact lenses used with three care systems

Conditions: Myopia

Summary: the objective of the study was to compare the clinical performance of the two contact lenses when used in combination with three care systems.

this was a randomized, open-label, crossover study, controlled by cross-comparison. subjects were randomized to wear each lens and solution combination for a month in random sequence; that is for a total of six months.

Eligibility criteria:
inclusion criteria: 1. they are aged 18-50 and have capacity to volunteer. 2. they understand their rights as a research subject and are willing and able to sign a statement of informed consent. 3. they are willing and able to follow the protocol. 4. they are an existing wearer of reusable, single vision, spherical soft contact lenses. 5. they have a contact lens spherical prescription between -1.00 to - 6.50d (inclusive) 6. they have a spectacle cylindrical correction of -1.00d or less in each eye. 7. at dispensing, they can attain at least 0.20 logmar distance high contrast visual acuity in each eye with the study lenses within the available power range. 8. they are willing to comply with the wear schedule (at least five days per week and for at least eight hours per day). 9. they agree not to participate in other clinical research for the duration of the study. exclusion criteria: 1. they have an ocular disorder which would normally contra-indicate contact lens wear. 2. they have a systemic disorder which would normally contra-indicate contact lens wear. 3. they are using any topical medication such as eye drops or ointment. 4. they have had cataract surgery. 5. they have had corneal refractive surgery. 6. they have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus. 7. they are pregnant or breastfeeding. 8. they have any ocular abnormality which would, in the opinion of the investigator, normally contraindicate contact lens wear. 9. they have any infectious disease which would, in the opinion of the investigator, contraindicate contact lens wear or pose a risk to study personnel; or they have any immunosuppressive disease (e.g. hiv), or a history of anaphylaxis or severe allergic reaction. 10. they have taken part in any other contact lens or care solution clinical trial or research, within two weeks prior to starting this study.
pilot study: the role of macrophage migration inhibitory factor (mif) in spinal cord injury

Conditions: Spinal Cord Injury

Summary: the purpose of the study is to investigate inflammatory and other substances that may be elevated in the blood and blood cells following spinal cord injury (sci). these substances will be evaluated in samples from people who have had a spinal cord injury due to trauma (e.g. car accident or a fall) within the first week (acute) or at least one year ago (chronic). specifically, the study will evaluate the presence and levels of a protein, macrophage migration inhibitory factor (mif). mif is released by cells and has a specific effect on the way cells behave, communicate and work together. in several other medical conditions, mif is known to increase inflammation in the body. by comparing blood samples from individuals with spinal cord injury and uninjured (no spinal cord injury) individuals, the investigators will try to find out if mif levels are increased in people with sci. investigators will also use these samples to measure other proteins that increase inflammation in the body and to see if the biological activities of mif can be reduced in a test tube by adding other substances to the blood samples. it is hoped that this study of mif and other proteins related to inflammation will help improve the treatment of sci in the future. we hope to enroll a total of 312 subjects in this study (50 with acute spinal cord injury, 125 with chronic spinal cord injury, and 137 uninjured individuals).

during the study visit the investigator will collect basic biographical information and health information, including some questionnaires, from the subjects and their medical record. acute sci subjects will also have blood drawn once daily (first blood draw will approximately be 2 tablespoons and subsequent blood draws will approximately be 1 tablespoon) . chronic sci subjects will have blood drawn per study visit (approximately 2 tablespoons) and will be asked to participate in two study visits, to take place 6 months apart.

Eligibility criteria:
inclusion criteria: sci subject inclusion criteria: to be eligible for prospective enrollment, subjects are required to meet the following inclusion criteria: * ≥18 years of age * history sci (acute or chronic): all american spinal injury association (asia) classifications a-d and all levels. healthy control subject inclusion criteria: to be eligible for prospective enrollment, healthy control subjects are required to meet the following inclusion criteria: * ≥18 years of age * the absence of any current or previous medical conditions to be eligible for prospective enrollment, sci subjects are required to not meet the following exclusion criteria: * \< 18 years of age * no known sci * concurrent infection such as uti * deep pressure sores * cancer, chemotherapy or neutropenia * autoimmune disease healthy control subject exclusion criteria: to be eligible for prospective enrollment, healthy control subjects are required to not meet the following exclusion criteria: * \< 18 years of age * current or previous medical conditions

Keywords: spinal cord injury
left ventricular capture management (lvcm) software download clinical trial

Conditions: Heart Failure

Summary: heart failure is a progressive disease that decreases the pumping action of the heart. this may cause a backup of fluid in the heart and may result in heart beat changes. when there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. in certain heart failure cases, when the two lower chambers of the heart no longer beat in a coordinated manner, cardiac resynchronization therapy (crt) may be prescribed. left ventricular capture management (lvcm) refers to the overall method for determining left ventricular thresholds (level of energy needed to effectively pace the tissue in the lower left chamber of the heart) by measuring, analyzing, and adjusting energy delivered from the crt device to the pacing lead. the purpose of the left ventricular capture management software download clinical trial was to evaluate the accuracy of the left ventricular capture management (lvcm) feature to support lvcm feature approval in future cardiac resynchronization therapy with defibrillation (crt-d) devices


Eligibility criteria:
inclusion criteria: * subjects who successfully underwent implantation of an insync ii marquis system exclusion criteria: * subjects who are post-heart transplant * subjects enrolled in a concurrent study that may confound the results of this study

Keywords: cardiac resynchronization therapy
transthoracic incremental monophasic versus biphasic by emergency responders (timber)

Conditions: Cardiac Arrest

Summary: the study compares the effectiveness of two fully approved shock waveforms (monophasic and biphasic shock) commonly used to defibrillate (shock) patients with out-of-hospital cardiac arrest due to a highly lethal rhythm problem (ventricular fibrillation). the purpose of the study (hypothesis) is to determine if one waveform results in improved resuscitation, admission alive to hospital, and discharge alive from hospital compared with the other.

the trial is designed to determine whether two fully-fda-approved, commercially available transthoracic defibrillation shock waveforms at comparable energies result in improved patient outcome following out-of-hospital cardiac arrest due to ventricular fibrillation. eligible subjects include all adults with nontraumatic out-of-hospital cardiac arrest due to ventricular fibrillation. subjects in cardiac arrest will be randomly allocated to receive one of two types of defibrillation shocks (monophasic or biphasic waveform) during their resuscitation, which will in addition include all other standard treatments. the primary endpoint is admission alive to hospital. secondary endpoints include rhythm after defibrillation shock, return of spontaneous circulation, and hospital discharge rates.

Eligibility criteria:
inclusion criteria: * adult victims of nontraumatic out-of-hospital cardiac arrest due to ventricular fibrillation exclusion criteria: * children * trauma

Keywords: cardiac arrest defibrillation biphasic defibrillation monophasic defibrillation ventricular fibrillation
anti-ficolin-2 autoantibodies in lupus nephritis

Conditions: Lupus Erythematosus, Systemic

Summary: systemic lupus erythematosus (sle) is a chronic autoimmune disease characterized by the production of multiple autoantibodies. the prevalence and significance of antibodies against ficolin-2 have not been yet investigated. the aims of this study were to determine the prevalence of anti-ficolin-2 antibodies among sle patients and to investigate their potential as diagnostic and/or prognostic biomarkers in sle. this study is a secondary phase of a serum sample analysis done in early 2015 in order to determine the prevalence of anti-ficolin-2 antibodies among the same cohort as the previously declared study (clinicaltrials.gov id: nct02625831; unique protocol id: 1841851v0). in this retrospective study, clinical data were obtained from medical files and blood samples were selected from preexisting biological collection. sle patients (n=165) were informed and did not objected, they were matched to healthy controls (n=48). disease activity was determined according to the sledai score. anti-ficolin-2 antibodies levels were measured in sera by elisa and correlated to previously obtained anti-ficolin-3, anti-ficolin-2, anti-dsdna and anti-c1q antibodies levels. the titer of anti-ficolin-2 antibodies was correlated with the sledai score (p\<0.0001). the presence of anti-ficolin-2 antibodies was associated with anti-ficolin-3 antibodies, anti-c1q and anti-dsdna antibodies. interestingly, the combination of anti-ficolin-3, anti-ficolin-2 and anti-c1q antibodies demonstrated higher specificity than any other traditional biomarker. these results suggest that anti-ficolin-3 and anti-ficolin-2 antibodies could be useful for the diagnosis of active nephritis in sle patients.

for this retrospective study, the well written brief summary should be sufficient.

Eligibility criteria:
165 sle patients inclusion criteria: * age: ≥ 18 years old * patients with lupus diagnostic criteria (acr1997) exclusion criteria: * pregnant women * patient with known evolutive cancer 48 healthy patients matched in age and sex with one or several sle patients

Keywords: ficolin-2 anti-ficolin-2 antibodies lupus nephritis lupus erythematosus, systemic biomarker ficolin-3 anti-ficolin-3 antibodies
topical palm tocotrienols on blemish-prone skin

Conditions: Acne

Summary: a single-center, double-blind, randomised, placebo-controlled parallel-group study. selected subjects will be randomised into active and control groups in a ratio of 1:1. investigational products assigned will be applied on the facial skin as part of daily skin care routine. the effects will be observed during the 12-weeks of use.


Eligibility criteria:
inclusion criteria: 1. healthy individuals, aged 18 years and above 2. fitzpatrick skin type ii to iv 3. blemish-prone skin with acne of severity grade 2 or 3 based on comprehensive acne severity scale (cass) exclusion criteria: 1. has a history of chronic drug or alcohol abuse 2. is a current smoker 3. history of severe allergic reactions to topical products or vitamin e 4. participant with severe and uncontrollable comorbidities (including but not limited to e.g. diabetes, hypertension, kidney failure) 5. pregnant, breastfeeding, or planning pregnancy 6. participant with known skin conditions (including but not limited to e.g. sensitive skin, eczema and diseased skin e.g. contact dermatitis), uncontrolled medical conditions, or any other condition that could interfere with the study evaluations or increase risk to the participant (such as polycystic ovary syndrome and contact dermatitis) 7. participant with compromised/broken skin, tattoos, scarring, excessive hair growth, very uneven skin tone, or other conditions that would interfere with evaluations or increase risk 8. participation in another study within 4 weeks of screening visit 9. has severe acne or acne conglobata 10. use of systemic treatment for acne such as isotretinoin, contraceptive pills, or spironolactone within 4 weeks of screening visit 11. use of topical treatments like antibiotics, corticosteroids, benzoyl peroxide, azelaic acid, salicylic acid, alpha hydroxy acids (ahas), vitamins a (retinol) or c (ascorbic acid) or their analogs or derivatives and other anti-inflammatory drugs within 2 weeks of screening visit 12. use of scrub, alpha-hydroxy acid (aha), skin irritant products in the 2 days before study treatment start 13. participant with active bacterial/fungal/viral skin infections or susceptibility to such infections within 2 weeks of screening visit 14. use oral antibiotics

Keywords: tocotrienol acne topical skin
the effect of paliperidone palmitate in schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is the evaluation of effectiveness of paliperidone palmitate within three different group of schizophrenia patients.

in this study, the investigators are going to examine the effectiveness of paliperidone palmitate after changing from other antipsychotics. this study design is a prospective naturalistic case series study. the effectiveness of paliperidone would be compared within three different groups of schizophrenia. investigators would also assess the safety during 24 weeks follow up period.

Eligibility criteria:
inclusion criteria: * age: 18 \~ 65 * patient with schizophrenia according to dsm-iv criteria * patient have signed on the informed consent, and well understood the objective and procedure of this study. * pansss total score \<120 * each score of disorganized thought, paranoia hallucinatory behavior, abnormal tbought contests \< 16 * three different groups ( other antipsychotics refractory schizophrenia patitents : cgi\> 4 chronic akathisia : diepss overall severity \>1, at least 1 month lasting symptoms poor compliance schizophrenia : crs \<3) * competent patient who is manage to answer the questionnaires. * in case of female at child-bearing age, consent to use appropriate contraceptive methods(oral pill, contraceptive injection, intrauterine device, double barrier method and contraceptive patch) during entire duration of this study. exclusion criteria: * no history of antipsychotics prescription * history of nms(neuroleptic malignant syndrome) * allergic reaction or hypersensitive reaction of risperidone or paliperidone er * clozapine medication within 1 month before screening * ssri, maoi, tca medication within 2 months * lithium, valproic acid, carbamazepine, topiramate, lamotrigine medication starting within 2 months * patient who is supposed to be impossible to participate to this study due to clinical risk of suicide or aggressive behavior based on clinician's opinion * current or previous history of drug depedence according to dsm-iv * pregnant or breast-feeding female patient * significant biochemical or hematological abnormality or abnormal finding of urinalysis, based on clinician's opinion * history of cardiac disease, which is related to qt prolongation(sick sinus, complete av block, chf, ventricular tachycardia, hypokalemia or hypocalcemia) * history of participating to other investigational drug trial within 1month prior to screening * investigator or employee at clinical trial center, personnel related to investigator or trial center on this or other study, or family of employee or investigator

Keywords: schizophrenia injection switch paliperidone refractory, chronic akathisia, poor complianc
safety and efficacy of ampligen in the treatment of hiv patients failing haart

Conditions: HIV Seropositivity; HIV Infection

Summary: this is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding ampligen to "haart" in hiv infected patients with cd4 counts \>300 and hiv-1 plasma rna \>500 and \<30,000 copies/ml (pcr).


Eligibility criteria:
1. adults at least 18 years of age. 2. cd4 cell count of \>300 cells. 3. hiv-1 plasma rna \>500 and \<30,000 copies/ml. a qualifying ("screening") hiv-1 rna level \>500 and \<30,000 copies/ml must be documented at least once within 40 days prior to starting baseline while patient is receiving a haart regimen containing at least two of the following antiretroviral drugs: * abacavir (ziagen) * zidovudine (retrovir) azt * zalcitabine (hivid) ddc * didanosine (videx) ddi * stavudine (zerit) d4t * efavirenz (sustiva) * indinavir (crixivan) * ritonavir (norvir) * nelfinavir (viracept) * amprenavir (agenerase) the patient must have been taking this haart regimen for four months or longer at the time of the qualifying hiv-1 rna determination. 4. history of prior treatment (including the current haart regimen) with at least one protease inhibitor (pi) and at least two nucleoside reverse transcriptase inhibitors (nrti) and/or at least one non-nucleoside reverse transcriptase inhibitor (nnrti) and at least two nucleoside reverse transcriptase inhibitors (nrti). 5. karnofsky performance status of at least 70. 6. the following laboratory parameters within 14 days prior to treatment: * hemoglobin \> 9.2 g/dl for men and \> 8.9 g/dl for women * neutrophil count \> 1000 * platelet count \> 75,000 * ast/alt \< 4.0 x upper limit of normal (uln) * serum creatinine \ 50 ml/min. 7. for females with child bearing potential: a negative serum pregnancy test within 14 days prior to randomization. males and females of child bearing potential agree to use an effective means of contraception.

Keywords: treatment experienced hiv infections hiv haart early virologic failure